Is Complement the Main Accomplice in IgA Nephropathy? From Initial Observations to Potential Complement-targeted Therapies
Overview
Molecular Biology
Affiliations
IgA Nephropathy (IgAN) is the main cause of primary glomerulonephritis, globally. This disease is associated with a wide range of clinical presentations, variable prognosis and a spectrum of histological findings. More than fifty years after its first description, this heterogeneity continues to complicate efforts to understand the pathogenesis. Nevertheless, involvement of the complement system in IgAN was identified early on. Dysfunction of the immunoglobulin A (IgA) system, the principal offender in this disease, including modification of isoforms and glycoforms of IgA1, the nature of immune complexes and autoantibodies to galactose deficient IgA1 might all be responsible for complement activation in IgAN. However, the specific mechanisms engaging complement are still under examination. Research in this domain should allow for identification of patients that may benefit from complement-targeted therapy, in the foreseeable future.
Role of serum complement C3 and C4 on kidney outcomes in IgA nephropathy.
Tringali E, Vetrano D, Tondolo F, Maritati F, Fabbrizio B, Pasquinelli G Sci Rep. 2024; 14(1):16224.
PMID: 39003309 PMC: 11246413. DOI: 10.1038/s41598-024-65857-w.
Challenges in IgA Nephropathy Management: An Era of Complement Inhibition.
Tesar V, Radhakrishnan J, Charu V, Barratt J Kidney Int Rep. 2023; 8(9):1730-1740.
PMID: 37705895 PMC: 10496078. DOI: 10.1016/j.ekir.2023.06.010.
Pathophysiology and clinical manifestations of immune complex vasculitides.
Sunderkotter C, Golle L, Pillebout E, Michl C Front Med (Lausanne). 2023; 10:1103065.
PMID: 36936215 PMC: 10020193. DOI: 10.3389/fmed.2023.1103065.
Shi D, Feng S, Zhong Z, Cai L, Wang M, Fu D Front Immunol. 2022; 13:973169.
PMID: 36311737 PMC: 9606215. DOI: 10.3389/fimmu.2022.973169.
Zhang S, Sun H, Zhang Z, Li M, Guo Z, Ye W Front Mol Biosci. 2022; 9:871615.
PMID: 35445079 PMC: 9014244. DOI: 10.3389/fmolb.2022.871615.